Integra LifeSciences Holdings Corporation reported a return to profitability in Q2 2026 following significant restructuring activities aimed at streamlining operations and addressing prior regulatory challenges. The company's two main segments—Codman Specialty Surgical (CSS) and Tissue Technologies (TT)—continue to drive revenue growth through product innovation and geographic expansion, especially in neurosurgery and regenerative biomaterials. However, ongoing quality system issues and EU Medical Device Regulation compliance have imposed additional costs, alongside the transition of manufacturing from Boston to Braintree. The company’s strong cash position and manageable leverage provide a buffer as it navigates these headwinds. Key indicators to watch include regulatory clearance progress, clinical evidence advancements, new product launches, and margin improvements driven by operational efficiencies.